Day Free Cash Flow from 2010 to 2024

DAWN Stock  USD 12.75  0.06  0.47%   
Day One Free Cash Flow yearly trend continues to be very stable with very little volatility. Free Cash Flow is likely to grow to about -142.6 M this year. Free Cash Flow is the amount of cash Day One Biopharmaceuticals generates after accounting for cash outflows to support operations and maintain its capital assets. View All Fundamentals
 
Free Cash Flow  
First Reported
2010-12-31
Previous Quarter
-150.1 M
Current Value
-142.6 M
Quarterly Volatility
53.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Day One financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Day One's main balance sheet or income statement drivers, such as Net Interest Income of 5.7 M, Depreciation And Amortization of 278.5 K or Interest Expense of 5.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.53. Day financial statements analysis is a perfect complement when working with Day One Valuation or Volatility modules.
  
Check out the analysis of Day One Correlation against competitors.

Latest Day One's Free Cash Flow Growth Pattern

Below is the plot of the Free Cash Flow of Day One Biopharmaceuticals over the last few years. It is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets. Day One's Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Day One's overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow10 Years Trend
Slightly volatile
   Free Cash Flow   
-13.6M-56.5M-109.9M-150.1M-142.6M100%
       Timeline  

Day Free Cash Flow Regression Statistics

Arithmetic Mean(34,521,343)
Coefficient Of Variation(156.07)
Mean Deviation42,800,504
Median(4,515,000)
Standard Deviation53,876,397
Sample Variance2902.7T
Range145.6M
R-Value(0.77)
Mean Square Error1265.9T
R-Squared0.60
Significance0.0008
Slope(9,292,850)
Total Sum of Squares40637.3T

Day Free Cash Flow History

2024-142.6 M
2023-150.1 M
2022-109.9 M
2021-56.5 M
2020-13.6 M

Other Fundumenentals of Day One Biopharmaceu

Day One Free Cash Flow component correlations

About Day One Financial Statements

Day One investors utilize fundamental indicators, such as Free Cash Flow, to predict how Day Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Free Cash Flow-150.1 M-142.6 M
Free Cash Flow Yield(0.13)(0.12)
Free Cash Flow Per Share(1.88)(1.98)
EV To Free Cash Flow(6.23)(6.54)
Price To Free Cash Flows Ratio(7.76)(8.15)
Free Cash Flow Operating Cash Flow Ratio 1.02  1.16 

Pair Trading with Day One

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.

Moving against Day Stock

  0.54DYAI Dyadic InternationalPairCorr
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out the analysis of Day One Correlation against competitors.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.97)
Revenue Per Share
1.144
Return On Assets
(0.25)
Return On Equity
(0.18)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

INZY
Inozyme Pharma
3.03  0.05  1.68 
PTGX
Protagonist Therapeutics
41.08  0.70  1.73 
PBYI
Puma Biotechnology
2.88  -0.04  -1.37 
SNDX
Syndax Pharmaceuticals
13.93  0.46  3.41 
News Freq…Investor S…